Rigel Pharmaceuticals Inc. (RIGL)
NASDAQ: RIGLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RIGL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $754.89M
- P/E (TTM)
- 2.49
- Forward P/E
- 8.39
- EPS (TTM)
- $16.07
- Dividend yield
- None
- 52-week range
- 24.95 – 52.61
- Day range
- 39.62 – 41.66
- Volume / Avg
- 352.03K / 248.06K
- Beta
- —
- Shares outstanding
- 18.83M
52-week range
RIGL stock today
On Nov 20, RIGL ended the session at $40.09, shedding $1.10 (2.67%), versus the S&P 500's 3.70% decline. At this level, RIGL sits in the middle of its 52-week range of $24.95 to $52.61: 23.8% below the high, set on Oct 30, 2026 and 60.7% above the low. RIGL is down 6.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 13.3%.
Rigel Pharmaceuticals trades at 2.5x its trailing twelve-month earnings per share of $16.07. Its forward P/E of 8.4x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Rigel Pharmaceuticals
Company profileRigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Raul R. Rodriguez
- Headquarters
- South San Francisco, CA
- Employees
- 172
- IPO year
- 2000
- Website
- rigel.com
Financial highlights
Full financialsIn fiscal 2025, Rigel Pharmaceuticals generated $294.3 million in revenue, up 64.1% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $367.0 million (+1999.1% year over year), for a net margin of 124.7% versus a median of -21.5% in the prior 5 years. Gross margin was 93.3% (up from 89.6%) and operating margin 42.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $294.28M | $179.28M | $116.88M | $120.24M | $149.24M |
| Growth | +64.15% | +53.38% | -2.79% | -19.43% | +37.39% |
| Net income | $367.02M | $17.48M | $-25.09M | $-58.57M | $-17.91M |
| EPS (diluted) | $19.48 | $0.99 | $-1.44 | $-3.44 | $-0.11 |
Analyst forecast
ForecastConsensus (4 analysts)
buy
Avg. price target
$64.40+60.64%
- Strong buy 0
- Buy 2
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $1.46 vs $0.87
- Surprise
- +67.82%
RIGL news
All RIGL news- Rigel to Present at the Jefferies Global Healthcare Conference in LondonPR Newswire
- Rigel (RIGL) Q3 2026 Earnings Call TranscriptNasdaq
- Rigel Pharmaceuticals GAAP EPS of $0.70 misses by $0.18, revenue of $80.9M beats by $0.8MSeeking Alpha
- United Therapeutics (UTHR) Q3 Earnings Miss EstimatesNasdaqUTHR, RIGL
- Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial ResultsPR Newswire
- Reasons Why Investors Should Consider Betting on Arvinas StockNasdaqARVN, PFE, RIGL
Rigel Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ARDXArdelyx Inc. | 2.99 | -2.29% | $751.60M | vs RIGL |
| IVAInventiva S.A. American Depository Shares | 3.14 | -8.99% | $750.78M | vs RIGL |
| ORICOric Pharmaceuticals Inc. | 7.36 | -4.42% | $764.94M | vs RIGL |
| COLLCollegium Pharmaceutical Inc. | 24.72 | -1.94% | $768.18M | vs RIGL |
| OBXObsidian Therapeutics Inc. | 12.00 | -1.23% | $741.29M | vs RIGL |
| IRWDIronwood Pharmaceuticals Inc. Class A | 4.70 | -0.21% | $778.09M | vs RIGL |
| SNDXSyndax Pharmaceuticals Inc. | 8.72 | -4.49% | $785.05M | vs RIGL |
| VSTMVerastem Inc. | 6.33 | -7.73% | $797.67M | vs RIGL |
Indexes, lists and sector
Rigel Pharmaceuticals stock FAQ
What is Rigel Pharmaceuticals's stock price today?
RIGL last traded at $40.09 as of Nov 20, 4:00 PM EST, down 2.67% on the day. Prices are delayed at least 15 minutes.
Does Rigel Pharmaceuticals pay a dividend?
No. Rigel Pharmaceuticals does not currently pay a regular cash dividend.
What is RIGL's P/E ratio?
RIGL trades at a trailing P/E ratio of 2.49 and a forward P/E of 8.39.
Who is Rigel Pharmaceuticals's CEO?
Mr. Raul R. Rodriguez is the chief executive officer of Rigel Pharmaceuticals Inc., which has about 172 employees.
Has RIGL ever split its stock?
Yes. The most recent RIGL stock split was a 1-for-10 split on Jun 27, 2024, one of 2 splits on record.
What is the RIGL 52-week high?
The 52-week high for RIGL is $52.61 and the 52-week low is $24.95. The stock is currently 23.8% below its high.